The effect on treatment comparisons of different measurement frequencies in human immunodeficiency virus observational databases.
Data collected in a routine clinical setting are frequently used to compare antiretroviral treatments for human immunodeficiency virus (HIV). Differences in the frequency of measurement of HIV RNA levels and CD4-positive T-lymphocyte cell counts introduce a possible source of bias into estimates of the difference in effectiveness between treatments. The authors investigated the size of this bias when survival analysis methods are used to compare the initial efficacy of antiretroviral regimens. Data sets of clinical markers were simulated by use of differential equations that model the interaction between HIV and human T-cells. Cox proportional hazards and parametric models were fitted to the simulated data sets to evaluate the bias and coverage of 95% confidence intervals for the difference between regimens. The authors' results demonstrate that differences in the frequency of follow-up can substantially bias estimated treatment differences if methods do not correctly account for the intervals between measurements and if the statistical model chosen does not fit the data well. Analyses using methods applicable to interval-censored data reduce the bias. In the Athena cohort of HIV-infected individuals in the Netherlands from 1999 to 2003, there are differences in measurement frequency between current regimens that are of sufficient magnitude to conclude incorrectly that some regimens are more effective than others.
Department of Infectious Disease Epidemiology, Faculty of Medicine, Imperial College, London, UK.
James T
JT
Griffin
Christophe
C
Fraser
Luuk
L
Gras
Frank
F
de Wolf
Azra C
AC
Ghani
D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D015982:Bias; D018791:CD4 Lymphocyte Count; D016208:Databases, Factual; D015658:HIV Infections / Q000188:drug therapy* / Q000453:epidemiology; D015497:HIV-1; D006801:Humans; D016015:Logistic Models; D009426:Netherlands / Q000453:epidemiology; D016016:Proportional Hazards Models; D012367:RNA, Viral / Q000097:blood; D016896:Treatment Outcome
D012367:RNA, Viral